Compare Stocks: LCTX, MLTX, CGEM, and ABUS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.78 +1.9%	$4.84	$3.50 ▼ $5.45	$929.12M	0.62	6.29 million shs	16.88 million shs
CGEM Cullinan Therapeutics	$15.35 +0.8%	$19.62	$5.68 ▼ $23.19	$980.12M	0.02	1.21 million shs	1.07 million shs
LCTX Lineage Cell Therapeutics	$0.96 +0.9%	$1.07	$0.91 ▼ $2.09	$239.63M	1.54	1.46 million shs	1.27 million shs
MLTX MoonLake Immunotherapeutics	$11.70 +2.2%	$15.38	$6.56 ▼ $23.29	$974.47M	1.04	1.69 million shs	1.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.92%	-1.44%	-5.91%	-1.85%	+5.29%
CGEM Cullinan Therapeutics	+0.79%	-9.01%	-30.45%	-12.93%	+158.85%
LCTX Lineage Cell Therapeutics	+0.87%	-0.10%	-13.12%	-29.21%	-43.45%
MLTX MoonLake Immunotherapeutics	+2.18%	-9.30%	-22.26%	-38.26%	+63.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$4.78 +1.9%	$4.84	$3.50 ▼ $5.45	$929.12M	0.62	6.29 million shs	16.88 million shs
CGEM Cullinan Therapeutics	$15.35 +0.8%	$19.62	$5.68 ▼ $23.19	$980.12M	0.02	1.21 million shs	1.07 million shs
LCTX Lineage Cell Therapeutics	$0.96 +0.9%	$1.07	$0.91 ▼ $2.09	$239.63M	1.54	1.46 million shs	1.27 million shs
MLTX MoonLake Immunotherapeutics	$11.70 +2.2%	$15.38	$6.56 ▼ $23.29	$974.47M	1.04	1.69 million shs	1.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	+1.92%	-1.44%	-5.91%	-1.85%	+5.29%
CGEM Cullinan Therapeutics	+0.79%	-9.01%	-30.45%	-12.93%	+158.85%
LCTX Lineage Cell Therapeutics	+0.87%	-0.10%	-13.12%	-29.21%	-43.45%
MLTX MoonLake Immunotherapeutics	+2.18%	-9.30%	-22.26%	-38.26%	+63.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	2.50	Moderate Buy	$5.00	4.60% Upside
CGEM Cullinan Therapeutics	2.78	Moderate Buy	$33.71	119.64% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$6.25	553.97% Upside
MLTX MoonLake Immunotherapeutics	2.43	Hold	$28.50	143.59% Upside

Current Analyst Ratings Breakdown

Latest LCTX, MLTX, CGEM, and ABUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $35.00
9/25/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/14/2026	CGEM Cullinan Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/26/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/24/2026	CGEM Cullinan Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CGEM Cullinan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$30.00
8/13/2026	CGEM Cullinan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$39.00 ➝ $42.00
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/12/2026	ABUS Arbutus Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$14.08M	67.26	N/A	N/A	$0.40 per share	11.95
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	$6.92 per share	N/A
LCTX Lineage Cell Therapeutics	$14.56M	16.60	N/A	N/A	$0.19 per share	5.03
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$33.50M	$0.79	6.05	N/A	N/A	84.22%	90.98%	82.34%	11/16/2026 (Estimated)
CGEM Cullinan Therapeutics	-$219.88M	-$3.10	N/A	N/A	N/A	N/A	-52.89%	-48.18%	11/5/2026 (Estimated)
LCTX Lineage Cell Therapeutics	-$63.53M	-$0.12	N/A	N/A	N/A	-246.58%	-73.06%	-30.87%	11/5/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)

Latest LCTX, MLTX, CGEM, and ABUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ABUS Arbutus Biopharma	-$0.02	-$0.03	-$0.01	-$0.03	$0.70 million	$1.01 million
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	CGEM Cullinan Therapeutics	-$0.7993	-$0.81	-$0.0107	-$0.81	$3.67 million	N/A
8/6/2026	Q2 2026	LCTX Lineage Cell Therapeutics	-$0.0283	-$0.03	-$0.0017	-$0.03	$1.84 million	$1.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CGEM Cullinan Therapeutics	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	81.42	81.42
CGEM Cullinan Therapeutics	N/A	8.42	8.42
LCTX Lineage Cell Therapeutics	N/A	6.61	6.61
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CGEM Cullinan Therapeutics	86.31%
LCTX Lineage Cell Therapeutics	62.47%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	19.90%
CGEM Cullinan Therapeutics	8.60%
LCTX Lineage Cell Therapeutics	24.70%
MLTX MoonLake Immunotherapeutics	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	19	198.11 million	158.68 million	Optionable
CGEM Cullinan Therapeutics	109	64.36 million	58.82 million	Optionable
LCTX Lineage Cell Therapeutics	77	252.91 million	190.44 million	Not Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable

LCTX, MLTX, CGEM, and ABUS Headlines

Recent News About These Companies

MoonLake files FDA application for sonelokimab therapy

September 30 at 5:11 PM | tipranks.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Now Rated "Moderate Buy" by Wall Street Analysts

September 29 at 2:15 AM | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rated "Moderate Buy" by Sell-Side Analysts

September 29 at 2:13 AM | marketbeat.com

Wall Street Zen Downgrades MoonLake Immunotherapeutics (NASDAQ:MLTX) to Strong Sell

September 27, 2026 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Bumped Down to Strong Sell by Wall Street Zen

September 27, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Sell at Wall Street Zen

September 19, 2026 | marketbeat.com

111,590 Shares in MoonLake Immunotherapeutics $MLTX Purchased by Engineers Gate Manager LP

September 15, 2026 | marketbeat.com

MLTX stock on track for worst week since last fall as FDA filing date for skin disease drug draws near

September 11, 2026 | msn.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Down 7.7% - Time to Sell?

September 9, 2026 | marketbeat.com

MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy

September 8, 2026 | seekingalpha.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Hold" by Brokerages

September 4, 2026 | marketbeat.com

MoonLake Immunotherapeutics (MLTX)

August 23, 2026 | finance.yahoo.com

MoonLake’s psoriatic arthritis drug shows promise in phase 3 trial – retail shrugs off premarket slide, says ‘pipeline is intact’

August 11, 2026 | msn.com

MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

August 10, 2026 | finance.yahoo.com

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical ...

August 10, 2026 | markets.businessinsider.com

MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

August 10, 2026 | benzinga.com

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

August 10, 2026 | reuters.com

MoonLake announces positive Phase 3 psoriatic arthritis results

August 10, 2026 | tipranks.com

MoonLake reports positive Phase 3 PsA data and $537 million cash

August 10, 2026 | quiverquant.comQ

MoonLake Immunotherapeutics GAAP EPS of -$0.84

August 10, 2026 | seekingalpha.com

MLTX stock under pressure as investors await psoriatic arthritis trial data

August 3, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, MLTX, CGEM, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$4.78 +0.09 (+1.92%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$4.78 +0.00 (+0.10%)

As of 09/30/2026 07:30 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Cullinan Therapeutics NASDAQ:CGEM

$15.35 +0.12 (+0.79%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$15.33 -0.02 (-0.13%)

As of 09/30/2026 07:56 PM Eastern

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.96 +0.01 (+0.87%)

Closing price 09/30/2026 04:10 PM Eastern

Extended Trading

$0.95 -0.01 (-1.01%)

As of 09/30/2026 07:30 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$11.70 +0.25 (+2.18%)

Closing price 09/30/2026 04:00 PM Eastern

Extended Trading

$11.84 +0.14 (+1.15%)

As of 09/30/2026 07:47 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LCTX, MLTX, CGEM, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LCTX, MLTX, CGEM, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LCTX, MLTX, CGEM, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, MLTX, CGEM, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Cullinan Therapeutics NASDAQ:CGEM

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LCTX, MLTX, CGEM, and ABUS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LCTX, MLTX, CGEM, and ABUS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LCTX, MLTX, CGEM, and ABUS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, MLTX, CGEM, and ABUS Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

Cullinan Therapeutics NASDAQ:CGEM

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools